Paul Horstmeier - Jan 5, 2022 Form 4 Insider Report for Health Catalyst, Inc. (HCAT)

Signature
/s/ Daniel Orenstein, as Attorney-in-Fact
Stock symbol
HCAT
Transactions as of
Jan 5, 2022
Transactions value $
-$225,066
Form type
4
Date filed
1/6/2022, 08:07 PM
Previous filing
Dec 29, 2021
Next filing
Feb 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HCAT Common Stock Options Exercise $65.4K +4.13K +4.27% $15.84 101K Jan 5, 2022 Direct
transaction HCAT Common Stock Options Exercise $105K +6.62K +6.57% $15.84 107K Jan 5, 2022 Direct
transaction HCAT Common Stock Sale -$153K -4.26K -3.96% $35.89 103K Jan 5, 2022 Direct F1, F2
transaction HCAT Common Stock Sale -$186K -5K -4.84% $37.15 98.2K Jan 5, 2022 Direct F1, F3
transaction HCAT Common Stock Sale -$56.9K -1.5K -1.52% $38.04 96.7K Jan 5, 2022 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HCAT Stock Option (Right to Buy) Options Exercise $0 -6.62K -49.45% $0.00 6.77K Jan 5, 2022 Common Stock 6.62K $15.84 Direct F5
transaction HCAT Stock Option (Right to Buy) Options Exercise $0 -4.13K -7.93% $0.00 47.9K Jan 5, 2022 Common Stock 4.13K $15.84 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 15, 2020, in accordance with Rule 10b5-1.
F2 Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $35.61 to $36.52, inclusive.
F3 Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $36.72 to $37.71, inclusive.
F4 Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $37.72 to $38.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes (2) through (4).
F5 25% of the 25,000 shares underlying the option vested in an annual installment and the remaining balance vested or will vest in equal monthly installments until the option vests in full on February 5, 2023.
F6 25% of the 186,467 shares underlying the option vested in an annual installment and the remaining balance vested or will vest in equal monthly installments until the option vests in full on February 5, 2023.